Perifollicular Transgenic Expression of Human Interleukin-1 Receptor Antagonist Protein following Topical Application of Novel Liposome-Plasmid DNA Formulations In Vivo

Niemiec, S. M.; Latta, Jill M.; Ramachandran, Chandrasekharan; Weiner, Norman; Roessler, Blake J.

doi:10.1021/js9604873

Cited by 35 publications

(15 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are some reports describing that liposomes have been used to enhance transfollicular and transdermal delivery of the low-/high-molecular weight and hydrophilic/lipophilic compounds (Fleisher et al, 1995;Li and Hoffman, 1996;Niemiec et al, 1997;Niemiec et al, 1995;Seiberg et al, 1997). However, we have confirmed that in vivo permeation of liposomes from the hair follicles into dermis/epidermis was not appeared under passive condition ( Supplementary Fig.…”

Section: Discussionsupporting

confidence: 66%

Noninvasive and persistent transfollicular drug delivery system using a combination of liposomes and iontophoresis

Kajimoto

Yamamoto

Watanabe

et al. 2011

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Iontophoresis is a promising technique for enhancing transdermal administration of charged drugs. However, conventional iontophoresis is not sufficient for effective delivery of large, hydrophilic, or electrically neutral molecules. In this study, we utilized charged liposomes as carriers, focused on a transfollicular route for delivery of the liposomes, and optimized iontophoretic conditions and lipid composition for this method in both in vitro and in vivo conditions.As a result, we identified the optimum condition (lipid composition:DOTAP/EPC/Chol=2:2:1, current supply: 0.45 mA/cm 2 , duration: 1 hr) for effective iontophoretic delivery of aqueous solution, which can not be transferred into the skin without charged liposomes. We also examined the pharmacological effects of iontophoresis of liposomes encapsulating insulin (INS-lipo) using a rat model of type I diabetes. Interestingly, iontophoresis of INS-lipo onto a diabetes rat skin resulted in a gradual decrease in blood glucose levels, with levels reaching 20% of initial values at 18 hr after administration. These lower blood glucose levels were maintained for up to 24 hr. Significant amount of insulin were also detected in plasma 18 hr after iontophoresis of INS-lipo. We succeeded in developing a non-invasive and persistent transfollicular drug delivery system that used a combination of liposomes and iontophoresis.

show abstract

Section: Discussionsupporting

confidence: 66%

Noninvasive and persistent transfollicular drug delivery system using a combination of liposomes and iontophoresis

Kajimoto

Yamamoto

Watanabe

et al. 2011

International Journal of Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…1 To accomplish optimal and prolonged gene expression the delivery vehicle plays an important role in protecting DNA from physical, chemical, and enzymatic destruction. Delivery vehicles that bind to DNA and facilitate transport to cellular targets include peptides, 2 glycopeptides, 3 glycosylated polymers, 4,5 cationic lipids, [6][7][8][9][10] liposomes, 11,12 and PLGA microspheres. 13 During fabrication of a delivery system the structure of DNA can be altered by shear stress to convert supercoiled plasmid to open circular, linear, or even fragmented DNA.…”

Section: Introductionmentioning

confidence: 99%

Stability of Peptide-Condensed Plasmid DNA Formulations

Adami

Collard

Gupta

et al. 1998

Journal of Pharmaceutical Sciences

157

106

View full text Add to dashboard Cite

Low molecular weight homogeneous peptides were used to form peptide/DNA condensates. A peptide possessing 18 lysines was found to protect plasmid DNA from serum endonuclease and sonicative-induced degradation whereas a shorter peptide possessing 8 lysines dissociated in 0.1 M sodium chloride and failed to protect DNA from enzymatic degradation. Peptide-condensed DNA showed no change in the ratio of supercoiled to circular DNA following 100 W sonication for up to 60 s and was able to transfect HepG2 cells with equivalent efficiency as untreated condensed plasmid DNA. Alternatively, uncondensed plasmid DNA was rapidly fragmented by sonication and serum endonucleases and resulted in negligible gene expression following condensation with peptide. Cationic lipid/DNA complexes were only partially effective at stabilizing DNA in serum compared to the complete stabilization afforded by peptide/DNA condensation. These results indicate that the stabilization afforded by condensation with a peptide protects DNA during formulation and preserves its structure in serum. These functions are important to achieve optimal gene expression from a nonviral gene delivery system.

show abstract

“…Expression of transgenic proteins could correct pertubances in cytokine production, the cause of several diseases affecting the skin. Liposomal delivery of IL-1receptor antagonist and expression of protein in the cells could inhibit the pathological effects of the endogenous IL-1 in skin cells, provided that the levels of the antagonist are 10-100 fold higher than the cytokine levels [101].…”

Section: Formulations and Delivery Systemsmentioning

confidence: 99%

DNA Delivery for Vaccination and Therapeutics Through the Skin

Földvári¹,

Babiuk²,

Badea

2006

CDD

View full text Add to dashboard Cite

Cutaneous gene therapy and DNA vaccination are potential applications of plasmid delivery methods where a gene for an antigen or a therapeutic protein is inserted in the plasmid and applied to the skin. However, the delivery of the DNA plasmid is a major challenge due to the unusual physicochemical properties of the DNA, the tissue and cellular barriers and expression difficulties. Even though the skin is the most accessible organ of the body and it is an ideal target for gene therapy, the delivery of plasmid DNA across the skin is very difficult due to the specific barrier function of the stratum corneum and the inconsistent transfection rate of keratinocytes and other epidermal cells. To date there is no gene delivery system that was shown to be optimal for cutaneous gene therapy. In order to develop an efficient non-viral delivery vehicle we need to design a system that provides the combined properties of effective DNA condensation, cutaneous permeation, cellular transfection and sufficiently sustained expression. This paper reviews the formulation approaches and delivery methods for DNA through the skin in the context of the barriers both at the tissue and cellular levels for both vaccine and gene therapy applications.

show abstract

Perifollicular Transgenic Expression of Human Interleukin-1 Receptor Antagonist Protein following Topical Application of Novel Liposome-Plasmid DNA Formulations In Vivo

Cited by 35 publications

References 27 publications

Noninvasive and persistent transfollicular drug delivery system using a combination of liposomes and iontophoresis

Noninvasive and persistent transfollicular drug delivery system using a combination of liposomes and iontophoresis

Stability of Peptide-Condensed Plasmid DNA Formulations

DNA Delivery for Vaccination and Therapeutics Through the Skin

Contact Info

Product

Resources

About